Previous 10 | Next 10 |
Immutep (IMMP) rises 11.7% after announcing data from its TACTI-002 and INSIGHT-004 studies. TACTI-002: Phase II trial evaluating the combination of eftilagimod alpha (efti) with Merck's Keytruda (pembrolizumab) in treatment of non-small cell lung cancer in first and second lin...
Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...
SYDNEY, AUSTRALIA, May 20, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce t...
This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc. As clinical data continues to strengthen, Immutep is seemingly well situated for pot...
SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from ...
SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from the Australian Federal Government’s R&D tax ...
Gainers: [[OTIC]] +10.4%. [[ASRV]] +5.2%. [[ANGI]] +3.3%. [[HLIT]] +2.7%. [[GDS]] +2.7%.Losers: [[VNET]] -7.7%. [[IMMP]] -5.1%. [[MIND]] -4.6%. [[AMRN]] -4.1%. [[TLSA]] -3.2%. For further details see: OTIC, HLIT, VNET and TLSA among after-hours movers
Provention Bio (PRVB) -38% after gives update on teplizumab BLA, FDA feedback.Virpax Pharmaceuticals (VRPX) -18%.Chemomab Therapeutics (CMMB) -17%.Iterum Therapeutics (ITRM) -15% after receiving notice from FDA on its NDA drug application for sulopenem etzadroxil/probenecid for...
Shares of Australia-based biotech Immutep Limited (NASDAQ: IMMP) rose sharply on Thursday thanks to the company's announcement of a regulatory update regarding one of its pipeline candidates, investigational cancer treatment eftilagimod alpha. Immutep Limited's stock ended the day u...
The FDA grants Fast Track designation to Immutep's (IMMP) lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, for the treatment of 1st line recurrent or metastatic head and neck squamous cell carcinoma ((HNSCC)).Fast Tr...
News, Short Squeeze, Breakout and More Instantly...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...